UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy

Annals of oncology, 2021-03, Vol.32 (3), p.295-297

2021

Volltextzugriff (PDF)

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Annals of oncology, 2017-08, Vol.28 (8), p.1988-1995

2017

Volltextzugriff (PDF)

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

Annals of oncology, 2022-02, Vol.33 (2), p.204-215

2022

Volltextzugriff (PDF)

Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444

Annals of oncology, 2018-10, Vol.29, p.viii403-viii404

2018

Volltextzugriff (PDF)

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

European journal of cancer (1990), 2017-02, Vol.72, p.S128-S129

2017

Volltextzugriff (PDF)

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma

Oncogene, 2011-03, Vol.30 (13), p.1542-1550

2011

Volltextzugriff (PDF)

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

Journal of clinical oncology, 1995-03, Vol.13 (3), p.688-696

1995

Volltextzugriff (PDF)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

The New England journal of medicine, 2015-07, Vol.373 (1), p.23-34

2015

Volltextzugriff (PDF)

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S34-S34

2014

Volltextzugriff (PDF)

Outcomes of Melanoma Brain Metastasis Management with Gamma Knife Radiosurgery +/- Ipilimumab

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S302-S303

2011

Volltextzugriff (PDF)

1224PPhase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1251P - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

Annals of oncology, 2019-10, Vol.30, p.v510-v510

2019

Volltextzugriff (PDF)

Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v500-v501

2019

Volltextzugriff (PDF)

1224P - Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Annals of oncology, 2019-10, Vol.30, p.v500-v501

2019

Volltextzugriff (PDF)

Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

Annals of oncology, 2019-10, Vol.30, p.v510

2019

Volltextzugriff (PDF)

1251PPathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

Cancer gene therapy, 2003-10, Vol.10 (10), p.737-744

2003

Volltextzugriff (PDF)

785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

Annals of oncology, 2022-09, Vol.33, p.S901

2022

Volltextzugriff (PDF)

1137PDIdentification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

A clinical development paradigm for cancer vaccines and related biologics

Journal of immunotherapy, 2007-01, Vol.30 (1), p.1-15

2007

Volltextzugriff (PDF)

3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy

Journal of vascular and interventional radiology, 2018-04, Vol.29 (4), p.S148-S148

2018

Volltextzugriff (PDF)

T-cell adoptive immunotherapy: moving ahead by going in a circle

The cancer journal (Sudbury, Mass.), 2000-03, Vol.6 (2), p.61

Sznol, M

2000

Volltextzugriff (PDF)

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Journal of clinical oncology, 1999-07, Vol.17 (7), p.2105-2116

1999

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion

Journal of clinical oncology, 2004-05, Vol.22 (9), p.1553-1563

2004

Volltextzugriff (PDF)

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

Journal of clinical oncology, 2002, Vol.20 (1), p.142-152

2002

Volltextzugriff (PDF)

1 – 25 von 318

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(307)
Mit Volltextzugriff
(271)

Publikationsform

Artikel
(316)
Reviews
(2)

Sprache

Englisch
(318)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444

Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Outcomes of Melanoma Brain Metastasis Management with Gamma Knife Radiosurgery +/- Ipilimumab

1224PPhase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

1251P - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

1224P - Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

1251PPathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

1137PDIdentification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444

A clinical development paradigm for cancer vaccines and related biologics

3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy

T-cell adoptive immunotherapy: moving ahead by going in a circle

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma

Suchergebnisse filtern